Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Joe E. who wrote (5281)	9/9/1998 4:57:00 PM
From: Vector1	Read Replies (1) \| Respond to of 6136

I have no information on a Dupont acquisition. However, the question of how the tracking stock affects a potential acquition is quite interesting. I would think it would make the deal more attractive to Dupont. Dupont would essentially be buying AGPH General which with conservative assumptions on synergies it could do for well north of $40 per share and still be accretive. Moreover they would have a built in sales force for Sustiva and a second generation version of Sustiva in development. The tracking stock would not affect Duponts earnings and would create a nice tax writeoff. V1

To: Joe E. who wrote (5281)	9/9/1998 5:05:00 PM
From: Izzy	Respond to of 6136

Besides the buyout rumors, AGPH's fundamentals look excellent. Book value is $7.65; Price/Book Value is only 3.66; debt to equity ratio is 2.5 (acceptable). Is it the general consensus that AGPH will easily beat the estimated EPS ($0.22) for the quarter ending 9/98 (scheduled to be reported 10-14-98)? And, any further discussion on how shareholders should vote regarding splitting the company? And, does anyone think that AGPH will buyout IMNR. My guess, if AGPH is to be bought out, is that it won't happen until 1999, once all other business has been completed. Personally, I would not even consider selling any of my shares for <40.